key: cord-0759617-5c35ug0j
authors: Hafer, Julia; Soumekh, Lisa; Thang, Christine
title: Erythema Nodosum after COVID-19 Vaccination in a Pediatric Patient
date: 2022-03-12
journal: JAAD Case Rep
DOI: 10.1016/j.jdcr.2022.03.009
sha: 6aae906c0f96f1d8967e62f0b7e998c4967d1dae
doc_id: 759617
cord_uid: 5c35ug0j

nan

As vaccination eligibility is extended to the pediatric population, further characterization of the 40 spectrum of cutaneous reactions in this population is needed. We describe a case of erythema 41 nodosum following COVID-19 vaccination in a pediatric patient. Laboratory testing was notable for an elevated erythrocyte sedimentation rate (ESR) of 62 37 mm/hr (<25 mm/hr) as well as elevated C-reactive protein (CRP) at 1.7 mg/dL (<0.8 mg/dL). 63

Complete blood count with differential was within normal limits. Antistreptolysin-O titers were 64 not elevated, and interferon-γ release assay was negative. idiopathic, but is also known to occur in the setting of infections, systemic inflammatory 77 conditions, medication use, pregnancy, and malignancy, among other conditions. 4 In the 78 pediatric population, group A beta-hemolytic streptococcal infection is the most common 79 trigger. 5 Regardless of etiology, the condition is generally self-limiting within three to six weeks 80 and resolves without long-term sequelae such as scarring or atrophy. 4 Diagnosis is based on 81 clinical presentation, but if presentation is atypical, skin biopsy can be considered. 5 We based 82 our diagnosis of EN on the classic clinical presentation and discussion with an on-site pediatric 83 dermatologist. Biopsy was deferred in our pediatric patient given the typical clinical findings 84 and course, and following consideration that biopsy would not likely change management. 6 85

The workup involves evaluating for common underlying etiologies including tuberculosis 86

(chest x-ray or interferon-γ release assays), streptococcus (antistreptolysin-O titers), and 87 malignancy (complete blood count). In the case of our patient, none of these tests revealed an 88 identifiable cause. Since vaccine-related reactions may occur up to six weeks following 89 inoculation according to the CDC's timeline for monitoring of COVID-19 vaccine safety, 7 we 90 considered our patient's recent COVID-19 vaccination to be the most likely underlying etiology 91 of her EN. Furthermore, vaccine-associated EN has been described previously up to 30 days 92 after the administration of other vaccines. 8 93 vaccination in the adult population. 2,3 Vaccine-related EN is generally assumed to represent a 98 reaction to the infectious antigen present in the vaccine, but it could theoretically also 99 represent a response to vaccine adjuvants. To the best of our knowledge, EN following COVID-100 19 vaccination has not yet been described in the pediatric population. 

Single-center clinico-pathological case study of 19 patients with cutaneous 128 adverse reactions following COVID-19 vaccines

CoV-2 vaccination: A case report

Erythema nodosum

Skin biopsy: Biopsy issues in specific 136 diseases

Possible side effects 139 after getting a COVID-19 vaccine

Combined reduced-antigen content tetanus, diphtheria, and 142 acellular pertussis (tdap) vaccine-related erythema nodosum: Case report and review of 143 vaccine-associated erythema nodosum